Post-Zika anti-NS1 serum IgA drives increased neutrophil functions in severe dengue disease

Authors:

Jaime A. Cardona-Ospina[1,2], Vicky Roy[3], Dorca E. Marcano-Jiménez[4], Sandra Bos[1], Elias Duarte[1], José V. Zambrana[5,6], Agamjot Bal[1], Antonio Gregorio Dias Jr.[1], Julia Zhiteneva[3], Julia Huffaker[1], Carlos Montenegro[5], Guillermina Kuan[5,7], Marcos J. Ramos-Benitez[4], Angel Balmaseda[5,8], Galit Alter[3], Eva Harris[1]*

Affiliations:

[1]Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA

[2]Grupo Biomedicina, Facultad de Medicina, Institución Universitaria Visión de las Américas, Pereira, Colombia

[3]Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA

[4]Department of Basic Sciences, Ponce Health Sciences University and Ponce Research Institute, Ponce, Puerto Rico

[5]Sustainable Sciences Institute, Managua, Nicaragua

[6]Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI

[7]Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua

[8]Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua

*Corresponding author. Email: eharris@berkeley.edu

Abstract

Primary immunity against Zika virus (ZIKV) increases the risk of a subsequent severe dengue virus 2 (DENV2) infection, presenting a significant challenge for developing safe and effective ZIKV vaccines. However, the mechanisms driving this phenomenon remain unclear. We show that post-ZIKV infection IgA antibodies in serum targeting the DENV2 nonstructural protein 1 (NS1) drive neutrophil activation and correlate with increased risk of a subsequent severe DENV2 infection in a pediatric cohort study. Increased neutrophil degranulation correlated with IgA binding to DENV2 NS1 and preceded vascular leakage in paired acute-phase samples from the same individuals and in dengue patients after prior ZIKV infection in an orthogonal hospital-based study. Thus, serum anti-NS1 IgA enhances neutrophil activation in severe dengue, with implications for prognostics, therapeutics, and vaccines.

Main Text

The four serotypes of dengue virus (DENV1-4) and Zika virus (ZIKV) are closely related flaviviruses that constitute the most prevalent causes of arboviral disease globally (*1*). DENV infections exhibit a clinical spectrum ranging from a self-limited febrile illness (dengue fever [DF]) to more severe, potentially fatal forms such as dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS) characterized by thrombocytopenia, vascular leakage, and hemorrhagic manifestations (*2*). Sequential infections with different DENV serotypes or ZIKV can either confer protection or increase the risk of subsequent severe disease (*3–5*). This phenomenon, primarily driven by the humoral immune response, presents significant challenges for the development of safe and effective vaccines.

During sequential DENV infections, sub-neutralizing cross-reactive IgG antibodies targeting structural viral proteins can facilitate viral entry into myeloid cells expressing Fcγ receptors, increasing viral load through a phenomenon known as antibody-dependent enhancement (ADE) (*6*, *7*). In addition, afucosylated IgG antibodies generated during the acute secondary infection further enhance disease severity by promoting cellular activation via FcγRIIIA (*8*, *9*). Epidemiological studies have shown that a primary ZIKV infection increases the likelihood of subsequent symptomatic DENV infections and severe disease (*4*, *5*). This association is strongly correlated with antibody levels, as a specific range of ZIKV-induced DENV cross-reactive antibodies are linked to an elevated risk of severe outcomes upon a subsequent DENV infection (*4*). Therefore, understanding the antibody features that underlie this increased risk is essential for developing safe and effective vaccines.

To explore this, we employed an agnostic systems serology approach to characterize DENV cross-reactive antibodies after a prior ZIKV infection and before a subsequent symptomatic infection with DENV2, leveraging unique serum samples from our long-standing Pediatric Dengue Cohort Study (PDCS) in Nicaragua (*10*). Our findings reveal that pre-existing IgA antibodies, particularly those targeting the nonstructural protein 1 (NS1), are key predictive features of DHF/DSS. Using systems serology and functional assays in paired pre-infection and acute-phase samples from the same individuals, we provide novel insights into the role of anti-NS1 IgA antibodies in mediating heightened neutrophil activation, a characteristic of children that progressed to severe disease. This insight reveals a previously unappreciated mechanism of IgA-mediated neutrophil activation in dengue disease that may underpin progression to severe disease in sequential flavivirus infections. These results have broad implications for understanding immune responses against flaviviruses in co-endemic regions and informing vaccine development. Moreover, they highlight the potential role of serum IgA antibodies in mediating neutrophil-mediated pathogenesis in infectious diseases.

Results

Pre-existing IgA antibodies differentiate severe and non-severe DENV infections

A prior ZIKV infection increases the risk of both symptomatic and severe disease during a subsequent DENV infection (*4*, *5*, *11*). While this elevated risk has been linked to DENV cross-reactive antibodies induced by ZIKV (*4*), the specific characteristics of these antibodies remain undefined. To address this gap, we employed an agnostic systems serology approach to evaluate the antigenic targets and isotypes of pre-existing antibodies associated with increased risk of DHF/DSS.

Our analysis focused initially on serum samples collected after primary ZIKV infection and before subsequent DENV2 infection from 24 children enrolled in the PDCS in Nicaragua. These children experienced a primary ZIKV infection in 2016, followed by a DENV2 infection in 2019–2020, which resulted in either DF (n = 14) or DHF/DSS (n = 10; Fig. 1A). Using a multiplexed bead-based assay (*12*), we characterized the antibody binding profile against the envelope protein (E), domain III of E (EDIII), and NS1 of DENV1–4 and ZIKV, evaluating total IgG, IgG1–4, IgM, and IgA antibodies.

After correcting for false discovery rate (FDR), only binding of IgA antibodies differed significantly between the clinical groups across all tested antigens and isotypes (fig. S1A). Additionally, increased ED_{50} values of IgA antibodies, reflecting the dilution at which binding is reduced to 50%, were uniquely associated with an elevated risk of developing DHF/DSS (Fig. 1B). In a regularized multivariate model, IgA binding to NS1 of the incoming serotype (DENV2) emerged as the variable with the highest adjusted coefficient, highlighting its strong association with severe disease outcomes (Fig. 1C).

To corroborate the discriminative potential of IgA binding suggested by the ED_{50} analysis, we assessed avidity by measuring antibody binding in the presence of urea as a chaotropic agent using our multiplexed bead-based assay (*13*). We compared the predictive performance for the development of DHF/DSS of IgA and IgG avidity. Notably, IgA avidity alone predicted DHF/DSS with an accuracy of 92% (95% CI: 62%–99%, p = 0.014; Fig. 1D), while IgG avidity neither predicted outcomes nor enhanced the model's performance (fig. S1B).

These findings established pre-existing high-avidity IgA antibodies induced after a primary ZIKV infection as key discriminative features associated with the development of DHF/DSS during a subsequent DENV2 infection.

Pre-existing anti-NS1 IgA antibodies drive neutrophil effector functions in children who developed DHF/DSS

Although IgA antibodies have been mainly studied in the context of mucosal immunity, they constitute the second most abundant immunoglobulin isotype in human serum, following IgG1 (*14*, *15*). Neutrophils are the primary and most abundant effectors of IgA antibodies (*16*). Notably, IgA-mediated neutrophil activation is thought to contribute to the pathogenesis of IgA-mediated immune diseases through formation of IgA-immune complexes (*17*). Several IgA-mediated immune diseases share clinical features with DHF/DSS, such as thrombocytopenia, arthralgia, petechiae and kidney involvement (*18*). Considering this, we investigated whether pre-existing IgA antibodies could enhance neutrophil effector functions and be associated with the development of severe dengue disease.

To evaluate whether pre-existing antibodies influence neutrophil activation, we evaluated antibody-dependent neutrophil effector functions in *ex vivo* functional assays. Considering that phagocytosis and NETosis are key neutrophil effector functions (*19*), we implemented *ex vivo* functional assays to measure antibody-dependent neutrophil phagocytosis (ADNP) and NETosis as a readout of antibody-dependent neutrophil activation. For ADNP, beads were coupled with either E or NS1 from the incoming serotype (DENV2). They were opsonized with the pre-infection serum of the participants and used to assess neutrophil phagocytosis of the beads via flow cytometry (*20*). Our results revealed that children who subsequently developed thrombocytopenia exhibited significantly higher ADNP against NS1 compared to those who did

not (fig. S2A). In fact, ADNP against NS1 consistently exceeded ADNP against E across different clinical endpoints (fig. S2A). This observation prompted a within-group comparison of ADNP responses to NS1 and E. We found that the serum from children who developed DHF/DSS or displayed hallmarks of severe disease consistently induced higher ADNP against NS1 than to E (Fig. 2A).

Considering this observation and given that IgA antibodies against DENV2 NS1 showed the highest adjusted coefficient in our multivariate model of antibody binding, we sought to determine whether the antibody-dependent neutrophil effector functions induced by pre-existing antibodies were specifically driven by IgA and targeted against NS1. To do this, we employed a complementary experimental approach. Due to the technical challenges of purifying IgA from small serum volumes, we compared the ability of IgA-depleted and mock-depleted serum to induce NETosis in an *ex-vivo* functional assay (*21*). In this assay, wells coated with either E or NS1 were incubated with IgA-depleted or mock-depleted pre-infection serum, and the induction of neutrophil extracellular traps (NETs) was quantified using a fluorescence-based assay. Importantly, in the absence of antibodies, E and NS1 induced minimal NET formation (fig. S2B). However, NS1 induced robust NETosis in the presence of IgA, and depleting IgA from the serum of children who developed DHF/DSS almost completely abrogated NET formation in response to NS1 (Fig. 2, B and D). In contrast, IgA depletion had no effect on NETosis induction in response to E (Fig. 2, B and C).

All together, these results demonstrate that pre-existing antibodies, particularly IgA targeting NS1, play a critical role in driving neutrophil effector functions, as evidenced by ADNP and NETosis in *ex vivo* functional assays.

Post-ZIKV severe DENV infections are characterized by enhanced neutrophil activation correlated with IgA binding to NS1

Consequently, we evaluated neutrophil involvement during the subsequent acute DENV2 infection in participants who progressed to DHF/DSS. To do this, we assessed serum samples obtained during the acute DENV2 infection of the same 24 participants (DF=14, DHF/DSS=10) from the PDCS. Initially, we evaluated circulating neutrophil levels during acute infection. On day three post-fever onset, just before the emergence of severe disease, children who progressed to DHF/DSS exhibited significantly higher relative neutrophil counts compared to those who developed DF (Fig. 3, A and B).

Next, we examined neutrophil degranulation, a key neutrophil effector function measurable in serum. We analyzed levels of components of primary granules (myeloperoxidase [MPO], neutrophil elastase [NE]), secondary granules (lactoferrin [LF]), and tertiary granules (matrix metalloproteinase 9 [MMP-9]) in serum collected on days 1-3 post-fever onset (Table S1). Importantly, primary granule components were significantly elevated in children with DHF/DSS and were associated with heightened risk of developing severe clinical manifestations, including mucosal bleeding, vascular leakage, and increased risk of ICU admission (Fig. 3, C and D).

Thereafter, we evaluated whether this enhanced neutrophil degranulation was correlated with antibody binding. In agreement with our experimental observation and statistical prediction in pre-infection samples, IgA binding to NS1 positively correlated with levels of primary granule components, while IgG antibodies correlated negatively with degranulation markers (Fig. 3E).

This highlights a distinct association between IgA antibodies targeting NS1 and heightened neutrophil activation early in the evolution to severe disease.

In this study, analysis of DENV2 viral loads during acute infection revealed no significant differences between clinical groups at the time of assessment (early post-fever onset; Fig. 3C), a finding also observed post-ZIKV DENV infections in a different population in Brazil (*11*).

These findings corroborate our experimental observations in pre-infection samples and *ex vivo* functional assays and demonstrate that severe post-ZIKV DENV infections are characterized by increased neutrophil activation that correlates with IgA antibodies in serum binding to NS1. Furthermore, these results highlight serum IgA antibodies directed against NS1 as key drivers of enhanced neutrophil activation during acute DENV2 infection.

Enhanced neutrophil activation precedes the development of vascular leakage and progression to DHF/DSS

To validate our findings, we investigated neutrophil involvement in the Pediatric Dengue Hospital-based Study (PDHS), an independent study conducted in Managua, Nicaragua. This study enrolls participants under 15 years of age presenting with acute febrile illness suspected of dengue; DENV infections are laboratory-confirmed and serotyped by RT-PCR (*22*). We screened children in the PDHS with DENV2 infections during the 2018–2020 epidemic to identify those with prior ZIKV exposure using our serotyping approach (*4*, *12*).

A total of 111 dengue cases with past ZIKV infections were identified (DF=67, DHF/DSS=44). Consistent with the PDCS observations, children who developed DHF/DSS exhibited significantly higher neutrophil counts compared to those with DF prior to progression to DHF/DSS (Fig. 4A and fig. S3A). We further explored neutrophil activation in a subset of samples (18 DHF/DSS and 36 DF cases) collected early after fever onset (≤3 days post fever onset), matched for age and sex. As in prior analyses, significantly elevated markers of neutrophil degranulation, particularly MPO and NE components of primary granules, were observed in individuals who progressed to DHF/DSS (Fig. 4B).

Finally, we investigated whether neutrophil degranulation preceded the development of vascular leakage, a defining feature of DHF/DSS. To address this, we used gallbladder wall thickness as a quantitative marker of vascular leakage (*23–25*). Gallbladder wall edema, a result of vascular leakage, is observed as DENV infection progresses to severe disease (Fig. 4C). This ultrasonographic metric provides a robust, continuous measure that is unaffected by treatment interventions and is widely and consistently employed in our setting for clinical triage and follow-up (*23*). We found that the maximum gallbladder wall thickness – typically reached on day 4 post-fever onset or later (Fig. 4C) – was positively correlated with levels of primary granule components measured on day 3 or earlier in both PDCS and PDHS participants (Fig. 4, D and E). These findings reveal that neutrophil activation precedes vascular leakage, implicating a role in the pathogenesis of severe dengue disease.

Discussion

The introduction of ZIKV into endemic regions of Latin America resulted in the widespread co-circulation of ZIKV and the closely related flaviviruses, DENV1-4. Like sequential DENV

infections with different serotypes, prior ZIKV immunity increases the risk of subsequent severe dengue disease (*4*, *5*). However, we and others found that post-ZIKV DENV infections that progress to severe disease do not exhibit the elevated viral load associated with antibody-enhanced DENV infections (*11*). This suggests that alternative immune mechanisms may contribute to the heightened risk of severe disease in these cases. To investigate these mechanisms, we focused on serum IgA, an often-overlooked antibody isotype in immune responses to infectious diseases. Our findings demonstrate that serum IgA antibodies targeting NS1 drive neutrophil activation in severe post-ZIKV dengue disease. Importantly, we establish a temporal relationship between pre-existing anti-NS1 IgA antibodies and heightened neutrophil activation during acute infection. In addition, we show that this increased neutrophil activation not only precedes but also correlates with the development of vascular leakage – a critical hallmark of severe dengue disease.

IgA antibodies in human serum are present at concentrations comparable to IgG3 and IgG2 (*14*, *15*). Although extensively studied in mucosal immunity, the role of IgA antibodies in human serum – whether protective or pathogenic – has been largely overlooked. This gap partly reflects limitations in mouse models, which naturally lack CD89 (Fc alpha receptor), a critical receptor for IgA on human myeloid cells (*26*). Of note, elevated IgA immune complexes have been implicated in autoimmune diseases through neutrophil activation; these diseases share clinical features with dengue, including rash, petechiae, thrombocytopenia, and kidney involvement (*17*, *18*, *27*). In the context of infectious diseases, serum IgA antibodies can mediate virus neutralization (*28*), and DENV IgA antibodies targeting structural components can block ADE and neutralize the virion (*29*). In contrast, our study demonstrates that IgA antibodies against soluble NS1, a non-structural protein that is secreted during infection, induce neutrophil activation in DHF/DSS cases preceding vascular leakage. While previous studies have reported DENV-associated IgA nephropathy and elevated titers of IgA in children with DHF/DSS (*30*, *31*), the absence of a temporal relationship between IgA responses and disease progression has hindered understanding of its role in DENV pathogenesis. By analyzing samples collected after primary ZIKV infection and prior to subsequent DENV2 infection, we establish a temporal link between pre-existing ZIKV-induced IgA antibodies targeting DENV NS1, heightened neutrophil activation, and progression to DHF/DSS in subsequent DENV2 infections.

Importantly, heightened neutrophil activation has consistently been associated with severe dengue disease in humans (*32–34*). Indeed, genes associated with increased neutrophil functions have been proposed as prognostic markers of severe dengue (*35*, *36*) Nevertheless, the link between neutrophil activation and pre-existing antibodies has remained elusive. DENV induces the production of immature neutrophils (*37*), which predominantly synthesize primary granules containing MPO and NE, degranulation markers associated with DHF/DSS. In parallel, serum IgA, to a greater extent than IgG, has been shown to enhance neutrophil effector functions during viral infections (*38*, *39*). Based on these observations and our results, we hypothesize that IgA/NS1 immune complexes drive heightened activation of immature neutrophils during infection, contributing to vascular dysfunction and organ damage. The pathogenic role of neutrophil activation has been well-documented in other infectious diseases, such as malaria and leishmaniasis (*40*, *41*). Although the current understanding of DHF/DSS immunopathogenesis is centered on the role of IgG antibodies targeting structural components of the virion in the context of ADE (*8*, *9*), we believe that enhanced neutrophil activation due to cross-reactive anti-NS1 IgA antibodies may contribute to disease pathogenesis in sequential DENV infections.

Nonetheless, our study has several limitations. Existing murine DENV disease models lack expression of the Fc alpha receptor (CD89) and exhibit IgA immunobiology distinct from humans (*26*). This limited our ability to validate IgA-mediated neutrophil activation as a direct cause of vascular leakage and severe disease. Instead, we conducted *ex vivo* functional assays using primary cells from healthy human donors, which demonstrated a strong association between IgA antibodies targeting NS1, neutrophil activation, and severe disease. We showed that IgA depletion in the presence of NS1 but not E significantly reduced neutrophil effector functions, underscoring the specificity of this response. On the other hand, although our findings suggest distinct roles for IgA antibodies targeting NS1 versus structural components such as E, the mechanisms underlying their differential contributions to neutrophil activation and disease pathogenesis remain unclear. Future studies are essential to elucidate these mechanisms and their broader consequences in the immunopathogenesis of viral infections.

Our study has several significant implications, we explored the pathogenic role of serum IgA antibodies, a frequently overlooked antibody isotype in immune responses. Our findings highlight the critical interplay between antigenic target and antibody isotype in disease and protection. While IgA antibodies targeting E can counteract ADE from IgG against the structural components of the virion (*29*) and IgG anti-NS1 antibodies confer protection against the virulent properties of NS1 (*42*, *43*), our results show that anti-NS1 IgA antibodies are implicated in severe disease. Furthermore, while we do not exclude IgG-mediated ADE, our observations support the presence of an alternative pathogenic pathway mediated by IgA antibodies and neutrophil activation in DENV infection. This highlights an interesting therapeutic avenue, since neutrophil functions can be targeted by approved and emerging drugs (*44*).

Finally, our findings enrich the current understanding of the role of pre-existing immunity in the immunopathogenesis of DHF/DSS. Using binding assays, *ex-vivo* functional assays, and validation of our observations in paired pre-infection and acute samples as well as an orthogonal dataset, we show that IgA antibodies drive neutrophil activation that correlates with increased risk of severe disease and precedes vascular leakage. We underscore the importance of antibody isotypes beyond IgG, such as IgA, and their antigenic targets (NS1 vs. E), with implications for refining therapeutic strategies and informing vaccine development. Further research into the precise mechanisms of IgA-mediated neutrophil activation is essential to fully unravel the pathways driving severe disease in the context of flaviviral and other infectious diseases.

References and Notes

1. S. Bhatt, P. W. Gething, O. J. Brady, J. P. Messina, A. W. Farlow, C. L. Moyes, J. M. Drake, J. S. Brownstein, A. G. Hoen, O. Sankoh, M. F. Myers, D. B. George, T. Jaenisch, G. R. William Wint, C. P. Simmons, T. W. Scott, J. J. Farrar, S. I. Hay, The global distribution and burden of dengue. *Nature* **496**, 504–507 (2013).
2. G. Paz-Bailey, L. E. Adams, J. Deen, K. B. Anderson, L. C. Katzelnick, Dengue. *The Lancet* **403**, 667–682 (2024).
3. L. C. Katzelnick, L. Gresh, M. E. Halloran, J. C. Mercado, G. Kuan, A. Gordon, A. Balmaseda, E. Harris, Antibody-dependent enhancement of severe dengue disease in humans. *Science (1979)* **358**, 929–932 (2017).
4. L. C. Katzelnick, C. Narvaez, S. Arguello, B. L. Mercado, D. Collado, O. Ampie, D. Elizondo, T. Miranda, F. B. Carillo, J. C. Mercado, K. Latta, A. Schiller, B. Segovia-Chumbez, S. Ojeda, N. Sanchez, M. Plazaola, J. Coloma, M. Elizabeth Halloran, L. Premkumar, A. Gordon, F. Narvaez, A. M. de Silva, G. Kuan, A. Balmaseda, E. Harris, Zika virus infection enhances future risk of severe dengue disease. *Science (1979)* **369**, 1123–1128 (2020).
5. J. V. Zambrana, C. M. Hasund, R. A. Aogo, S. Bos, S. Arguello, K. Gonzalez, D. Collado, T. Miranda, G. Kuan, A. Gordon, A. Balmaseda, L. C. Katzelnick, E. Harris, Primary exposure to Zika virus is linked with increased risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1. *Sci Transl Med* **16**, 2199 (2024).
6. A. Yamanaka, H. A. Imad, W. Phumratanaprapin, J. Phadungsombat, E. Konishi, T. Shioda, Antibody-dependent enhancement representing in vitro infective progeny virus titer correlates with the viremia level in dengue patients. *Sci Rep* **11** (2021).
7. J. J. Waggoner, L. C. Katzelnick, R. Burger-Calderon, J. Gallini, R. H. Moore, G. Kuan, A. Balmaseda, B. A. Pinsky, E. Harris, Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections. *J Infect Dis* **221**, 1846–1854 (2020).
8. S. Bournazos, H. T. M. Vo, V. Duong, H. Auerswald, S. Ly, A. Sakuntabhai, P. Dussart, T. Cantaert, J. V. Ravetch, Antibody fucosylation predicts disease severity in secondary dengue infection. *Science (1979)* **372**, 1102–1105 (2021).
9. R. Yamin, K. S. Kao, M. R. MacDonald, T. Cantaert, C. M. Rice, J. V. Ravetch, S. Bournazos, Human FcγRIIIa activation on splenic macrophages drives dengue pathogenesis in mice. *Nat Microbiol* **8**, 1468–1479 (2023).
10. A. Gordon, G. Kuan, J. C. Mercado, L. Gresh, W. Avilés, A. Balmaseda, E. Harris, The Nicaraguan Pediatric Dengue Cohort Study: Incidence of Inapparent and Symptomatic Dengue Virus Infections, 2004-2010. *PLoS Negl Trop Dis* **7** (2013).
11. C. F. Estofolete, A. F. Versiani, F. S. Dourado, B. H. G. A. Milhim, C. C. Pacca, G. C. D. Silva, N. Zini, B. F. Dos Santos, F. A. Gandolfi, N. F. B. Mistrão, P. H. C. Garcia, R. S. Rocha, L. Gehrke, I. Bosch, R. E. Marques, M. M. Teixeira, F. G. da Fonseca, N. Vasilakis, M. L. Nogueira, Influence of previous Zika virus infection on acute dengue episode. *PLoS Negl Trop Dis* **17** (2023).
12. S. Bos, J. V. Zambrana, E. Duarte, A. L. Graber, J. Huffaker, C. Montenegro, L. Premkumar, A. Gordon, G. Kuan, A. Balmaseda, E. Harris, Serotype-specific epidemiological patterns of inapparent versus symptomatic primary dengue virus infections: a 17-year cohort study in Nicaragua. *Lancet Infect Dis*, doi: 10.1016/S1473-3099(24)00566-8 (2024).

13. C. T. Perciani, P. S. Peixoto, W. O. Dias, F. S. Kubrusly, M. M. Tanizaki, Improved method to calculate the antibody avidity index. *J Clin Lab Anal* **21**, 201–206 (2007).
14. P. G. Shackelford, D. M. Granoff, J. V Madassery, M. G. Scott, M. H. Nahm, Clinical and Immunologic Characteristics of Healthy Children with Subnormal Serum Concentrations of IgG2. *Pediatr Res* **27**, 16–21 (1990).
15. A. Plebani, A. G. Ugazio, M. A. Avanzini, P. Massimi, L. Zonta, V. Monafo, G. R. Burgio, Serum IgG subclass concentrations in healthy subjects at different age: Age normal percentile charts. *Eur J Pediatr* **149**, 164–167 (1989).
16. U. Steffen, C. A. Koeleman, M. V. Sokolova, H. Bang, A. Kleyer, J. Rech, H. Unterweger, M. Schicht, F. Garreis, J. Hahn, F. T. Andes, F. Hartmann, M. Hahn, A. Mahajan, F. Paulsen, M. Hoffmann, G. Lochnit, L. E. Muñoz, M. Wuhrer, D. Falck, M. Herrmann, G. Schett, IgA subclasses have different effector functions associated with distinct glycosylation profiles. *Nat Commun* **11**, 120 (2020).
17. S. Mayer-Hain, K. Gebhardt, M. Neufeld, J. M. Ehrchen, K. Molyneux, J. Barratt, E. Nattkemper, D. Gerloff, J. Roth, T. Vogl, K. I. Pappelbaum, C. Sunderkötter, Systemic Activation of Neutrophils by Immune Complexes Is Critical to IgA Vasculitis. *J Immun* **209**, 1048–1058 (2022).
18. E. Pillebout, IgA Vasculitis and IgA Nephropathy: Same Disease? *J Clin Med* **10**, 2310 (2021).
19. A. Aroca-Crevillén, T. Vicanolo, S. Ovadia, A. Hidalgo, Neutrophils in Physiology and Pathology. *Annu Rev Pathol* **19**, 227–259 (2024).
20. A. G. Dias, C. Atyeo, C. Loos, M. Montoya, V. Roy, S. Bos, P. Narvekar, T. Singh, L. C. Katzelnick, G. Kuan, D. A. Lauffenburger, A. Balmaseda, G. Alter, E. Harris, Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. *Sci Transl Med* **14**, 3151 (2022).
21. J. R. Strich, M. J. Ramos-Benitez, D. Randazzo, S. R. Stein, A. Babyak, R. T. Davey, A. F. Suffredini, R. W. Childs, D. S. Chertow, Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. *J Infect Dis* **223**, 981–984 (2021).
22. F. Narvaez, C. Montenegro, J. G. Juarez, J. V. Zambrana, K. Gonzalez, E. Videa, S. Arguello, F. Barrios, S. Ojeda, M. Plazaola, N. Sanchez, D. Camprubí-Ferrer, G. Kuan, G. Paz Bailey, E. Harris, A. Balmaseda, Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua. *PLoS Negl Trop Dis* **19**, e0012811 (2025).
23. J. A. Colbert, A. Gordon, R. Roxelin, S. Silva, J. Silva, C. Rocha, E. Harris, Ultrasound measurement of gallbladder wall thickening as a diagnostic test and prognostic indicator for severe dengue in pediatric patients. *Pediatr Infect Dis J* **26**, 850–852 (2007).
24. B. D. C. Ferreira, D. Correia, Ultrasound Assessment of Hepatobiliary and Splenic Changes in Patients With Dengue and Warning Signs During the Acute and Recovery Phases. *J Ultrasound Med* **38**, 2015–2024 (2019).
25. A. Srikiatkhachorn, A. Krautrachue, W. Ratanaprakarn, L. Wongtapradit, N. Nithipanya, S. Kalayanarooj, A. Nisalak, S. J. Thomas, R. V. Gibbons, M. P. Mammen, D. H. Libraty, F. A. Ennis, A. L. Rothman, S. Green, Natural History of Plasma Leakage in Dengue Hemorrhagic Fever. *Pediatr Infect Dis J* **26**, 283–290 (2007).
26. R. C. Monteiro, Y. Suzuki, Are there animal models of IgA nephropathy? *Semin Immunopathol* **43**, 639–648 (2021).
27. G. Seminario, M. E. Gonzalez-Serrano, C. S. Aranda, A. S. Grumach, G. R. S. Segundo, L. Regairaz, A. A. Cardona, J. C. A. Becerra, C. Poli, A. King, F. R. Fernandes, L. Leiva,

J. L. Franco, F. J. Espinosa-Rosales, R. Sorensen, B. T. Costa Carvalho, L. Bezrodnik, A. Condino-Neto, The Latin American Society for Immunodeficiencies Registry. *J Clin Immunol* **45**, 28 (2024).

28. Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, C. Viant, C. Gaebler, M. Cipolla, H.-H. Hoffmann, T. Y. Oliveira, D. A. Oren, V. Ramos, L. Nogueira, E. Michailidis, D. F. Robbiani, A. Gazumyan, C. M. Rice, T. Hatziioannou, P. D. Bieniasz, M. Caskey, M. C. Nussenzweig, Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Sci Transl Med* **13**, 1555 (2021).
29. A. D. Wegman, M. J. Waldran, L. E. Bahr, J. Q. Lu, K. E. Baxter, S. J. Thomas, A. T. Waickman, DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection. *PLoS Pathog* **19**, e1011616 (2023).
30. B. K. Upadhaya, A. Sharma, A. Khaira, A. K. Dinda, S. K. Agarwal, S. C. Tiwari, Transient IgA nephropathy with acute kidney injury in a patient with dengue fever. *Saudi J Kidney Dis Transpl* **21**, 521–5 (2010).
31. R. Bachal, K. Alagarasu, A. Singh, A. Salunke, P. Shah, D. Cecilia, Higher levels of dengue-virus-specific IgG and IgA during pre-defervescence associated with primary dengue hemorrhagic fever. *Arch Virol* **160**, 2435–2443 (2015).
32. P. Y. Chia, A. Teo, T. W. Yeo, Association of Neutrophil Mediators with Dengue Disease Severity and Cardiac Impairment in Adults. *J Infect Dis* **226**, 1974–1984 (2022).
33. P. Loke, S. N. Hammond, J. M. Leung, C. C. Kim, S. Batra, C. Rocha, A. Balmaseda, E. Harris, Gene expression patterns of dengue virus-infected children from nicaragua reveal a distinct signature of increased metabolism. *PLoS Negl Trop Dis* **4** (2010).
34. M. Recker, W. A. Fleischmann, T. H. Nghia, N. Van Truong, L. Van Nam, D. Duc Anh, L. H. Song, N. T. The, C. X. Anh, N. V. Hoang, N. M. Truong, N. L. Toan, P. G. Kremsner, T. P. Velavan, Markers of prolonged hospitalisation in severe dengue. *PLoS Negl Trop Dis* **18** (2024).
35. M. Robinson, T. E. Sweeney, R. Barouch-Bentov, M. K. Sahoo, L. Kalesinskas, F. Vallania, A. M. Sanz, E. Ortiz-Lasso, L. L. Albornoz, F. Rosso, J. G. Montoya, B. A. Pinsky, P. Khatri, S. Einav, A 20-Gene Set Predictive of Progression to Severe Dengue. *Cell Rep* **26**, 1104-1111.e4 (2019).
36. Y. E. Liu, S. Saul, A. M. Rao, M. L. Robinson, O. L. Agudelo Rojas, A. M. Sanz, M. Verghese, D. Solis, M. Sibai, C. H. Huang, M. K. Sahoo, R. M. Gelvez, N. Bueno, M. I. Estupiñan Cardenas, L. A. Villar Centeno, E. M. Rojas Garrido, F. Rosso, M. Donato, B. A. Pinsky, S. Einav, P. Khatri, An 8-gene machine learning model improves clinical prediction of severe dengue progression. *Genome Med* **14**, 33 (2022).
37. S. Duggal, S. Rawat, G. Siddqui, P. Vishwakarma, S. Samal, A. Banerjee, S. Vrati, Dengue virus infection in mice induces bone marrow myeloid cell differentiation and generates Ly6Glow immature neutrophils with modulated functions. *J Leukoc Biol* **115**, 130–148 (2024).
38. H. D. Stacey, D. Golubeva, A. Posca, J. C. Ang, K. E. Novakowski, M. A. Zahoor, C. Kaushic, E. Cairns, D. M. E. Bowdish, C. E. Mullarkey, M. S. Miller, IgA potentiates NETosis in response to viral infection. *Proc Natl Acad Sci U S A* **118** (2021).
39. A.-K. Gimpel, A. Maccataio, H. Unterweger, M. V. Sokolova, G. Schett, U. Steffen, IgA Complexes Induce Neutrophil Extracellular Trap Formation More Potently Than IgG Complexes. *Front Immunol* **12** (2022).
40. S. L. Knackstedt, A. Georgiadou, F. Apel, U. Abu-Abed, C. A. Moxon, A. J. Cunnington, B. Raupach, D. Cunningham, J. Langhorne, R. Krüger, V. Barrera, S. P. Harding, A. Berg, S. Patel, K. Otterdal, B. Mordmüller, E. Schwarzer, V. Brinkmann, A. Zychlinsky, B.

Amulic, Neutrophil extracellular traps drive inflammatory pathogenesis in malaria. *Sci Immunol* **4**, 336 (2019).

41. K. Passelli, B. Prat-Luri, M. Merlot, M. Goris, M. Mazzone, F. Tacchini-Cottier, The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis. *PLoS Pathog* **18** (2022).
42. S. B. Biering, D. L. Akey, M. P. Wong, W. Clay Brown, N. T. N. Lo, H. Puerta-Guardo, F. T. G. de Sousa, C. Wang, J. R. Konwerski, D. A. Espinosa, N. J. Bockhaus, D. R. Glasner, J. Li, S. F. Blanc, E. Y. Juan, S. J. Elledge, M. J. Mina, P. Robert Beatty, J. L. Smith, E. Harris, Structural basis for antibody inhibition of flavivirus NS1–triggered endothelial dysfunction. *Science (1979)* **371**, 194–200 (2021).
43. N. Modhiran, H. Song, L. Liu, C. Bletchly, L. Brillault, A. A. Amarilla, X. Xu, J. Qi, Y. Chai, S. T. M. Cheung, R. Traves, Y. X. Setoh, S. Bibby, C. A. P. Scott, M. E. Freney, N. D. Newton, A. A. Khromykh, K. J. Chappell, D. A. Muller, K. J. Stacey, M. J. Landsberg, Y. Shi, G. F. Gao, P. R. Young, D. Watterson, A broadly protective antibody that targets the flavivirus NS1 protein. *Science (1979)* **371**, 190–194 (2021).
44. T. Németh, M. Sperandio, A. Mócsai, Neutrophils as emerging therapeutic targets. *Nat Rev Drug Discov* **19**, 253–275 (2020).
45. A. Gordon, G. Kuan, W. Aviles, N. Sanchez, S. Ojeda, B. Lopez, L. Gresh, A. Balmaseda, E. Harris, The Nicaraguan pediatric influenza cohort study: design, methods, use of technology, and compliance. *BMC Infect Dis* **15**, 504 (2015).
46. F. Narvaez, G. Gutierrez, M. A. Pérez, D. Elizondo, A. Nuñez, A. Balmaseda, E. Harris, Evaluation of the Traditional and Revised WHO Classifications of Dengue Disease Severity. *PLoS Negl Trop Dis* **5**, e1397 (2011).
47. A. Balmaseda, J. V. Zambrana, D. Collado, N. García, S. Saborío, D. Elizondo, J. C. Mercado, K. Gonzalez, C. Cerpas, A. Nuñez, D. Corti, J. J. Waggoner, G. Kuan, R. Burger-Calderon, E. Harris, Comparison of Four Serological Methods and Two Reverse Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. *J Clin Microbiol* **56** (2018).
48. J. J. Waggoner, L. Gresh, A. Mohamed-Hadley, G. Ballesteros, M. J. V. Davila, Y. Tellez, M. K. Sahoo, A. Balmaseda, E. Harris, B. A. Pinsky, Single-Reaction Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. *Emerg Infect Dis* **22**, 1295–1297 (2016).
49. J. J. Waggoner, J. Abeynayake, M. K. Sahoo, L. Gresh, Y. Tellez, K. Gonzalez, G. Ballesteros, A. M. Pierro, P. Gaibani, F. P. Guo, V. Sambri, A. Balmaseda, K. Karunaratne, E. Harris, B. A. Pinsky, Single-Reaction, Multiplex, Real-Time RT-PCR for the Detection, Quantitation, and Serotyping of Dengue Viruses. *PLoS Negl Trop Dis* **7**, e2116 (2013).
50. A. Gordon, L. Gresh, S. Ojeda, L. C. Katzelnick, N. Sanchez, J. C. Mercado, G. Chowell, B. Lopez, D. Elizondo, J. Coloma, R. Burger-Calderon, G. Kuan, A. Balmaseda, E. Harris, Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. *PLoS Med* **16**, e1002726 (2019).
51. J. Cohen, *Statistical Power Analysis for the Behavioral Sciences* (Lawrence Erlbaum Associates, ed. 2nd, 2013).
52. B. W. Johnson, B. J. Russell, R. S. Lanciotti, Serotype-Specific Detection of Dengue Viruses in a Fourplex Real-Time Reverse Transcriptase PCR Assay. *J Clin Microbiol* **43**, 4977–4983 (2005).
53. A. G. Dias, E. Duarte, J. V. Zambrana, J. A. Cardona-Ospina, S. Bos, V. Roy, G. Kuan, A. Balmaseda, G. Alter, E. Harris, Complement-dependent virion lysis mediated by dengue-

Zika virus cross-reactive antibodies correlates with protection from severe dengue disease. *medRxiv*, doi: 10.1101/2024.06.03.24308395 (2024).

54. S. T. Kudlacek, S. Metz, D. Thiono, A. M. Payne, T. T. N. Phan, S. Tian, L. J. Forsberg, J. Maguire, I. Seim, S. Zhang, A. Tripathy, J. Harrison, N. I. Nicely, S. Soman, M. K. McCracken, G. D. Gromowski, R. G. Jarman, L. Premkumar, A. M. de Silva, B. Kuhlman, Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies. *Sci Adv* **7**, 4084–4099 (2021).

Acknowledgments: We thank the study personnel at the Centro de Salud Sócrates Flores Vivas, the Nicaraguan National Virology Laboratory, the Hospital Infantil Manuel de Jesús Rivera, and the Sustainable Sciences Institute in Nicaragua. We are particularly grateful to the study participants and their families. We would also like to thank Olivia Cuaresma for her technical support and Dr. Jeffrey R. Strich and Kiana Allen for their contributions to prior development of the NETosis assay.

Funding: This work was supported by NIH/NIAID grants P01AI106695 (EH) and U01AI153416 (EH). The Nicaraguan cohort and hospital studies were supported by NIH/NIAID grants U19AI118610 (EH), R01 AI099631 (AB), P01AI106695 (EH), and U01AI153416 (EH). MJRB is supported by funding from the Research Centers in Minority Institutions (RCMI) Center for Research Resources Grant and the Molecular and Genomics Core (U54MD007579) and the Hispanic Alliance for Clinical and Translational Research - Mentor Mentee Program Grant (5U54GM133807-03)

Author contributions:

Conceptualization: JACO, EH

Methodology: JACO, EH, SB, JVZ, VR, BB, MJRB, GA

Investigation: JACO, ED, AB, DEMJ, VR, BB, JZ, JH, AGD

Visualization: JACO

Funding acquisition: EH, GA, MJRB

Project administration: EH

Supervision: EH

Writing – original draft: JACO, EH

Writing – review & editing: JACO, EH, SB, JVZ, AGD, VR, BB, MJRB, DEMJ, GA, JZ, JH

Competing interests: EH laboratory received research funds from Takeda Vaccines Inc. to test samples from vaccine recipients. EH served on one-time advisory boards for Merck and Takeda. G.A. was an employee of Moderna Therapeutics and holds equity in Leyden Labs and Systems Seromyx. The other authors declare that they have no competing interests.

Data and materials availability: All data associated with this study are present in the main text or supplementary materials. The associated code is available for reference on Zenodo. Reference

code and datasets for antibody profiling and coefficient adjustment using regularization (DOI: 10.5281/zenodo.14837883), reference code for assessing the classification performance of IgA, IgG, and IgG/IgA avidity (DOI: 10.5281/zenodo.14837889), and source data for figures (DOI: 10.5281/zenodo.14837915). After securing approval from the UC Berkeley Committee for the Protection of Human Subjects, individual data for figure reproduction can be shared with external researchers. For data access arrangements, please contact E.H. at eharris@berkeley.edu. Standard data and material transfer agreements govern all data used in this study.

Supplementary Materials

Materials and Methods

Figs. S1 to S3

Table S1

References (*45–54*)



Fig 1. Study design and antibody profiling of post-ZIKV DENV2 cases in the Pediatric Dengue Cohort Study. (**A**) Study workflow. (i) Sample selection: serum samples from children

with primary ZIKV infection (2016) who developed dengue fever (DF, n=14) or dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS, n=10) during a subsequent DENV2 infection (2019–2020) were analyzed. (ii) Antibody binding analysis was performed in pre-infection samples (after the primary ZIKV infection and before the subsequent DENV2 infection). (iii) *Ex vivo* functional assays with pre-infection antibodies were performed to analyze neutrophil activation, and (iv) neutrophil involvement during acute infection was assessed using paired acute-phase samples. (v) The statistical approach involved bivariate and multivariate analysis. (**B**) Heatmaps display the odds ratio of developing DHF/DSS for IgG, IgM, and IgA binding to the antigens tested. Significance: *$p<0.05$, **$p<0.01$ after False Discovery Rate (FDR) correction. (**C**) Adjusted coefficients via regularization reveal NS1 DENV2 binding as the strongest predictor of disease severity. (**D**) Total IgA avidity discriminates DF and DHF/DSS cases, shown by OPLS-DA (Accuracy=0.92, [95% CI=0.62–1], p=0.015, R2Y=0.715, Q2=0.473). Blue dots: DF; red dots: DHF/DSS.



Fig. 2. IgA antibodies targeting NS1 induce enhanced neutrophil activation in severe dengue cases. (**A**) Antibody-dependent neutrophil phagocytosis (ADNP) normalized phagocytic scores across clinical groups and severe disease manifestations. Data points represent the average of two replicates from two different healthy donors per sample (DF=14, DHF/DSS=10). Children with DHF/DSS exhibited significantly higher ADNP against NS1 compared to E, particularly in association with plasma leakage (p=0.014) and thrombocytopenia (p=0.004). The data indicate a skewed neutrophil activation response toward NS1 in severe cases. (**B**) Representative microscopy images of NETosis assays. Panels compare mock-depleted plasma (left) and IgA-depleted plasma (right) for E and NS1 antigens. IgA depletion significantly reduces NET formation in NS1-coated wells (p=0.038), highlighting the role of IgA in mediating neutrophil activation. Red arrows indicate NETs. Scale bar=200 µm. (**C**, **D**) Quantification of percent change in NETosis signal for E (**C**) and NS1 (**D**) antigens after IgA depletion. Data points represent the percent change comparing paired depleted and mock-depleted samples from participants who developed DF (n=14) or DHF/DSS (n=10). While no significant difference was observed for E, NETosis was significantly reduced in DHF/DSS cases when NS1-specific IgA

was depleted.



Fig 3. Enhanced neutrophil activation during acute infection correlates with disease severity and binding of anti-NS1 IgA1 antibodies. (**A**) Relative leukocyte proportions, platelet counts, and hematocrit levels in DF and DHF/DSS cases over time. Day 3 post-fever onset is marked with a dashed red line. (**B**) Neutrophil counts on day 3 post-fever onset—prior to the onset of thrombocytopenia (platelet count<100,000/µL)—were significantly elevated in children who progressed to DHF/DSS (p=0.012). (**C**) Levels of primary granule markers (myeloperoxidase [MPO], neutrophil elastase [NE]), secondary granule markers (lactoferrin), tertiary granule markers (MMP-9), NETs, and viral loads among children with DF or DHF/DSS. DHF/DSS cases displayed higher levels of MPO (p=0.018) and NE (p=0.054), with no significant differences in viral loads. (**D**) Logistic regression shows significant correlation between MPO, NE, and severe outcomes such as ICU admission and pleural effusion (OR with 95% CI). (**E**) Correlation heatmaps between antibody binding and neutrophil degranulation. Only significant correlations (adjusted p-value<0.05) after FDR correction are displayed. IgA1 binding to NS1 positively correlates with MPO and NE, while IgG inversely correlates, highlighting distinct antibody roles in neutrophil activation.



Fig. 4. Neutrophil activation precedes and correlates with vascular leakage during acute dengue infection across two independent cohort studies. (**A**) Relative neutrophil count in DF or DHF/DSS cases in the Pediatric Dengue Hospital Study (PDHS). Consistent with findings from the Pediatric Dengue Cohort Study (PDCS), DHF/DSS cases had significantly higher relative neutrophil count compared to DF cases (p=0.022). (**B**) Levels of neutrophil degranulation markers, (myeloperoxidase [MPO], neutrophil elastase [NE], lactoferrin [LF], and matrix metalloproteinase-9 [MMP-9]) in DHF/DSS vs. DF cases. DHF/DSS cases in the PDHS showed significantly elevated MPO (p=0.023) and NE (p=0.005) levels. AFU: Arbitrary fluorescent units, OD: Optic density. Data points represent the average of two technical replicates from DF (n=36) or DHF/DSS (n=18) cases. Outliers were excluded from analysis. (**C**) Gallbladder wall thickness over time in DF and DHF/DSS cases in the PDHS and PDCS. Greater gallbladder wall thickening was observed in DHF/DSS cases during acute infection, reflecting increased vascular leakage. (**D**, **E**) Correlation analyses between neutrophil degranulation and gallbladder thickness in the PDCS (**D**) and PDHS (**E**). A positive correlation is observed between NE levels (measured on/before day 3 post-fever onset) and maximum gallbladder wall thickness in the PDCS ($p<0.001$, $R^2=0.35$) and PDHS ($p=0.01$, $R^2=0.128$).